CYTOKINETICS, INCORPORATED Earnings Per Share, Basic and Diluted
CYTOKINETICS, INCORPORATED (CYTK) reported Earnings Per Share, Basic and Diluted of -$1.05 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-06
- CYTOKINETICS, INCORPORATED earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$1.05.
- CYTOKINETICS, INCORPORATED earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.95.
- CYTOKINETICS, INCORPORATED earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.86.
- CYTOKINETICS, INCORPORATED earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.66.
- CYTOKINETICS, INCORPORATED earnings per share, basic and diluted for fiscal 2021 was -$2.80.
- CYTOKINETICS, INCORPORATED earnings per share, basic and diluted for fiscal 2020 was -$1.97.
- CYTOKINETICS, INCORPORATED earnings per share, basic and diluted for fiscal 2019 was -$2.11.
- CYTOKINETICS, INCORPORATED earnings per share, basic and diluted for fiscal 2018 was -$1.95.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 6 month as first filed | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 9 month as first filed | Earnings Per Share, Basic and Diluted 12 month | Earnings Per Share, Basic and Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | -$1.05 10-Q · filed 2022-05-06 | |||||||
| 2021-12-31 | -$2.80 10-K · filed 2022-02-25 | |||||||
| 2021-09-30 | -$0.95 10-Q · filed 2021-11-05 | -$2.48 10-Q · filed 2021-11-05 | ||||||
| 2021-06-30 | -$0.86 10-Q · filed 2021-08-06 | -$1.52 10-Q · filed 2021-08-06 | ||||||
| 2021-03-31 | -$0.66 10-Q · filed 2022-05-06 | |||||||
| 2020-12-31 | -$1.97 10-K · filed 2022-02-25 | |||||||
| 2020-09-30 | -$0.05 10-Q · filed 2021-11-05 | -$1.34 10-Q · filed 2021-11-05 | ||||||
| 2020-06-30 | -$0.68 10-Q · filed 2021-08-06 | -$1.35 10-Q · filed 2021-08-06 | ||||||
| 2020-03-31 | -$0.66 10-Q · filed 2021-05-07 | |||||||
| 2019-12-31 | -$2.11 10-K · filed 2022-02-25 | |||||||
| 2019-09-30 | -$0.50 10-Q · filed 2020-11-06 | -$1.60 10-Q · filed 2020-11-06 | ||||||
| 2019-06-30 | -$0.56 10-Q · filed 2020-08-07 | -$1.09 10-Q · filed 2020-08-07 | ||||||
| 2019-03-31 | -$0.54 10-Q · filed 2020-05-08 | |||||||
| 2018-12-31 | -$1.95 10-K · filed 2021-02-26 | |||||||
| 2018-09-30 | -$0.40 10-Q · filed 2019-11-01 | -$1.47 10-Q · filed 2019-11-01 | ||||||
| 2018-06-30 | -$0.51 10-Q · filed 2019-08-09 | -$1.07 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | -$0.56 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$2.59 10-K · filed 2019-03-07 | |||||||
| 2017-09-30 | -$0.60 10-Q · filed 2018-11-09 | -$1.82 10-Q · filed 2018-11-09 | ||||||
| 2017-06-30 | -$0.60 10-Q · filed 2018-08-07 | -$1.22 10-Q · filed 2018-08-07 | ||||||
| 2017-03-31 | -$0.62 10-Q · filed 2018-05-10 | |||||||
| 2016-06-30 | -$0.29 10-Q · filed 2017-08-04 | -$0.61 10-Q · filed 2017-08-04 | ||||||
| 2016-03-31 | -$0.31 10-Q · filed 2017-05-04 | |||||||
| 2015-12-31 | -$0.97 10-K · filed 2016-03-03 | |||||||
| 2015-09-30 | -$0.23 10-Q · filed 2015-11-05 | -$0.73 10-Q · filed 2015-11-05 | ||||||
| 2015-06-30 | -$0.27 10-Q · filed 2016-08-04 | -$0.50 10-Q · filed 2016-08-04 | ||||||
| 2015-03-31 | -$0.23 10-Q · filed 2016-05-05 | |||||||
| 2014-12-31 | $0.23 derived: net income ÷ weighted average shares · filed 2016-03-03 | $0.07 derived: net income ÷ weighted average shares · filed 2016-03-03 | -$0.16 derived: net income ÷ weighted average shares · filed 2016-03-03 | -$0.41 10-K · filed 2016-03-03 | ||||
| 2014-09-30 | -$0.16 10-Q · filed 2015-11-05 | -$0.39 derived: net income ÷ weighted average shares · filed 2015-11-05 | -$0.65 10-Q · filed 2015-11-05 | -$0.49 derived: net income ÷ weighted average shares · filed 2016-03-03 | ||||
| 2014-06-30 | -$0.23 10-Q · filed 2015-08-05 | -$0.49 10-Q · filed 2015-08-05 | -$0.32 derived: net income ÷ weighted average shares · filed 2016-03-03 | -$0.72 derived: net income ÷ weighted average shares · filed 2016-03-03 | ||||
| 2014-03-31 | -$0.27 10-Q · filed 2015-05-04 | -$0.07 derived: net income ÷ weighted average shares · filed 2016-03-03 | -$0.48 derived: net income ÷ weighted average shares · filed 2016-03-03 | -$1.01 derived: net income ÷ weighted average shares · filed 2016-03-03 | ||||
| 2013-12-31 | $0.22 derived: net income ÷ weighted average shares · filed 2016-03-03 | -$0.20 derived: net income ÷ weighted average shares · filed 2016-03-03 | -$0.74 derived: net income ÷ weighted average shares · filed 2016-03-03 | -$1.24 10-K · filed 2016-03-03 | ||||
| 2013-09-30 | -$0.43 10-Q · filed 2014-11-06 | -$1.00 derived: net income ÷ weighted average shares · filed 2015-03-06 | -$1.52 10-Q · filed 2014-11-06 | -$2.01 derived: net income ÷ weighted average shares · filed 2015-03-06 | ||||
| 2013-06-30 | -$0.58 10-Q · filed 2014-08-07 | -$1.11 10-Q · filed 2014-08-07 | -$1.60 derived: net income ÷ weighted average shares · filed 2015-03-06 | -$2.05 derived: net income ÷ weighted average shares · filed 2015-03-06 | ||||
| 2013-03-31 | -$0.53 10-Q · filed 2014-05-07 | -$0.09 10-Q · filed 2013-05-08 | -$1.01 derived: net income ÷ weighted average shares · filed 2015-03-06 | -$1.46 derived: net income ÷ weighted average shares · filed 2015-03-06 | -$2.12 derived: net income ÷ weighted average shares · filed 2015-03-06 | |||
| 2012-12-31 | -$0.48 derived: net income ÷ weighted average shares · filed 2015-03-06 | -$0.93 derived: net income ÷ weighted average shares · filed 2015-03-06 | -$1.60 derived: net income ÷ weighted average shares · filed 2015-03-06 | -$2.30 10-K · filed 2015-03-06 | -$0.38 10-K · filed 2013-03-15 | |||
| 2012-09-30 | -$0.45 10-Q · filed 2013-11-06 | -$0.07 10-Q · filed 2012-11-07 | -$1.13 derived: net income ÷ weighted average shares · filed 2014-03-07 | -$1.86 10-Q · filed 2013-11-06 | -$0.31 10-Q · filed 2012-11-07 | $3.29 derived: net income ÷ weighted average shares · filed 2014-03-07 | ||
| 2012-06-30 | -$0.76 10-Q · filed 2013-08-07 | -$0.13 10-Q · filed 2012-08-06 | -$1.54 10-Q · filed 2013-08-07 | -$0.26 10-Q · filed 2012-08-06 | $1.31 derived: net income ÷ weighted average shares · filed 2014-03-07 | $131.16 derived: net income ÷ weighted average shares · filed 2014-03-07 | ||
| 2012-03-31 | -$0.13 10-Q · filed 2013-05-08 | $0.50 derived: net income ÷ weighted average shares · filed 2014-03-07 | $6.56 derived: net income ÷ weighted average shares · filed 2014-03-07 | -$3.48 derived: net income ÷ weighted average shares · filed 2014-03-07 | ||||
| 2011-12-31 | $0.07 derived: net income ÷ weighted average shares · filed 2014-03-07 | $0.50 derived: net income ÷ weighted average shares · filed 2014-03-07 | $5.92 derived: net income ÷ weighted average shares · filed 2014-03-07 | -$4.30 10-K · filed 2014-03-07 | -$0.72 10-K · filed 2013-03-15 | |||
| 2011-09-30 | -$0.15 10-Q · filed 2012-11-07 | -$0.38 derived: net income ÷ weighted average shares · filed 2013-03-15 | -$0.55 10-Q · filed 2012-11-07 | |||||
| 2011-06-30 | -$0.23 10-Q · filed 2012-08-06 | -$0.41 10-Q · filed 2012-08-06 | ||||||
| 2011-03-31 | -$0.18 10-Q · filed 2012-05-04 | |||||||
| 2010-12-31 | -$0.77 10-K · filed 2013-03-15 | |||||||
| 2010-09-30 | -$0.19 10-Q · filed 2011-11-04 | -$0.59 10-Q · filed 2011-11-04 | ||||||
| 2010-06-30 | -$0.21 10-Q · filed 2011-08-04 | -$0.40 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |